Liminatus Pharma (LIMN) vs PharmaCyte Biotech (PMCB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Liminatus Pharma is the larger company by market cap ($5.0 million vs $4.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LIMN | PMCB |
|---|---|---|
| Share price | $3.69 | $0.3974 |
| Market cap | $4.96M | $4.27M |
| 1-day change | -4.65% | -2.02% |
| EPS (TTM) | $-23.50 | $-2.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $141.50 | $1.51 |
| 52-week low | $3.29 | $0.3339 |
| Distance from 52-week high | -97.39% | -73.68% |
| Average volume | 453.28K | 205.72K |
| Shares outstanding | 1.34M | 10.74M |
| Employees | 1 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Liminatus Pharma
LIMN stock →Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1 employees
About PharmaCyte Biotech
PMCB stock →PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2 employees
LIMN vs PMCB FAQ
Which is bigger, Liminatus Pharma or PharmaCyte Biotech?
Liminatus Pharma (LIMN) is larger, with a market capitalization of $4.96M compared with $4.27M for PharmaCyte Biotech (PMCB).
Are Liminatus Pharma and PharmaCyte Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.